CINECA IRIS Institutional Research Information System

CAVALLO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.211
EU - Europa 3.694
AS - Asia 2.181
SA - Sud America 114
OC - Oceania 94
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.344
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.020
CN - Cina 1.274
IT - Italia 857
IE - Irlanda 466
SE - Svezia 362
FR - Francia 320
DE - Germania 289
GB - Regno Unito 258
JP - Giappone 226
FI - Finlandia 172
AT - Austria 168
UA - Ucraina 168
CA - Canada 146
IN - India 145
KR - Corea 145
PL - Polonia 130
ES - Italia 118
VN - Vietnam 90
AU - Australia 84
CH - Svizzera 66
NL - Olanda 59
BE - Belgio 52
HK - Hong Kong 52
GR - Grecia 48
TH - Thailandia 44
TR - Turchia 42
RU - Federazione Russa 40
MX - Messico 34
BR - Brasile 31
TW - Taiwan 30
SG - Singapore 24
PT - Portogallo 23
SN - Senegal 23
IL - Israele 22
AR - Argentina 19
DK - Danimarca 19
PE - Perù 18
SA - Arabia Saudita 17
CL - Cile 15
HU - Ungheria 15
NO - Norvegia 15
CO - Colombia 14
UZ - Uzbekistan 13
RO - Romania 12
PH - Filippine 11
NZ - Nuova Zelanda 10
IR - Iran 9
MY - Malesia 9
ZA - Sudafrica 9
CZ - Repubblica Ceca 8
PK - Pakistan 7
BY - Bielorussia 6
EC - Ecuador 6
BO - Bolivia 5
EU - Europa 5
CU - Cuba 4
EG - Egitto 4
HR - Croazia 4
MK - Macedonia 4
SK - Slovacchia (Repubblica Slovacca) 4
VE - Venezuela 4
OM - Oman 3
PS - Palestinian Territory 3
AL - Albania 2
AM - Armenia 2
BD - Bangladesh 2
DZ - Algeria 2
GE - Georgia 2
JO - Giordania 2
MT - Malta 2
NG - Nigeria 2
PR - Porto Rico 2
SC - Seychelles 2
SV - El Salvador 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BS - Bahamas 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ID - Indonesia 1
IM - Isola di Man 1
IQ - Iraq 1
KE - Kenya 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
MN - Mongolia 1
PA - Panama 1
SI - Slovenia 1
UG - Uganda 1
Totale 11.344
Salva come PNG Salva come JPEG
Città #
Beijing 556
Chandler 547
Dublin 459
Fairfield 278
Houston 253
Ashburn 200
Redwood City 196
Torino 169
Jacksonville 165
Vienna 159
Ann Arbor 154
Wilmington 140
Woodbridge 133
Princeton 129
Nyköping 127
Seattle 123
Villeurbanne 120
Dearborn 119
Medford 112
Shanghai 110
Cambridge 98
Warsaw 82
San Mateo 76
Duncan 70
Milan 63
Pisa 61
Fremont 55
Boston 53
Tokyo 48
Dong Ket 47
Rome 46
Guangzhou 45
London 44
Nanjing 44
Turin 41
Boardman 39
Chengdu 39
Washington 39
Hangzhou 37
Toronto 32
New York 31
Florence 30
Norwalk 30
Brussels 29
Zhengzhou 29
Bologna 28
Athens 27
Hebei 27
Rochester 27
Sydney 26
Ottawa 25
Taipei 24
Atlanta 23
Chennai 23
San Diego 22
Central 21
Paris 21
Chicago 19
Jinan 19
Madrid 19
Barcelona 18
Collegeville 18
Lima 18
Ankara 17
Philadelphia 17
Bangkok 16
Hefei 16
Fuzhou 15
Polska 15
Hyderabad 14
Los Angeles 14
San Francisco 14
Seoul 14
Tianjin 14
Xian 14
Changsha 13
Munich 13
Wuhan 13
Budapest 12
Des Moines 12
Brisbane 11
Buenos Aires 11
Central District 11
Jerusalem 11
Melbourne 11
Mumbai 11
Phoenix 11
Verona 11
Brooklyn 10
Columbus 10
Guiyang 10
Bangalore 9
Bengaluru 9
Berlin 9
Chongqing 9
Durham 9
Mississauga 9
Nanchang 9
New Delhi 9
Palermo 9
Totale 6.304
Salva come PNG Salva come JPEG
Nome #
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial 1.436
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study 749
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 514
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma 482
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 448
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma 413
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 309
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 291
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents 286
Role of consolidation/maintenance therapy in multiple myeloma. 215
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 201
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. 199
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 176
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide 176
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials 143
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies 138
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 137
AISF position paper on HCV in immunocompromised patients 115
Psychological distress and oral chemotherapy: a pilot study. 112
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) 109
High-risk myeloma: when to transplant-or not. 103
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 103
Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL 97
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. 94
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 93
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 93
CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE IN MULTIPLE MYELOMA 92
12p, 1p, 1q, 5q, 11q ABNORMALITIES AND IMMUNOPHENOTYPE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA. 92
Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma 90
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 89
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 87
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients. 83
Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide 82
THROMBOPROPHYLAXIS FOR NEWLY DIAGNOSED MULTIPLEMYELOMA PATIENTS TREATED WITH LENALIDOMIDE-BASEDREGIMENS: A RANDOMIZED PHASE III STUDY OF ASPIRINVS ENOXAPARIN 81
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives. 81
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients 79
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 79
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 79
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 78
Droplet Digital PCR Assay for MYD88L265P 77
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients 76
Oral chemotherapy: an innovative choice 76
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS. 76
Real life use of bendamustine in elderly patients with lymphoid neoplasia 76
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 75
A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis. 72
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 70
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 69
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 69
The treatment of the elderly multiple myeloma patients 67
MULTIPLE MYELOMA: CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE 67
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma 65
Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol 65
Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3) 63
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 62
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR 61
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma 61
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 59
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study 58
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial 58
CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE IN MULTIPLE MYELOMA 58
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation 56
Clinical and biological features of multiple myeloma involving the gastrointestinal system 55
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients 55
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant 52
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 52
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. 48
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma 48
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment 48
Hyperammonemia and encephalopathy in patients with multiple myeloma 47
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. 47
Response to bortezomib and activation of osteoblasts in multiple myeloma 47
Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma 46
Review of thalidomide in the treatment of newly diagnosed multiple myeloma 46
Oral melphalan, prednisone,and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 46
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 46
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. 45
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 45
Piedmont and Aosta Valley Consortium of Systemic Amyloidosis: results of a four year experience 44
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 43
Lenalidomide and its role in the management of multiple myeloma 42
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 41
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 41
The hemostatic system and malignancy 40
Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma 40
Defibrotide: a review on clinical use and future development. 40
INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA 39
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III. 39
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. 37
INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) DETEDTION OF CHROMOSOME 13 ABNORMALITIES (DEL 13) IN MULTIPLE MYELOMA 37
Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases 37
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 36
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy 35
Stem cell mobilization in newly diagnosed multiple myeloma patients after lenalidomide 35
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 35
Phase I study of the anti insulin-like growth factor1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and incombination with bortezomib in patients with relapsed multiple myeloma. 34
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)) 34
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma 33
Farnesyltransferase inhibitors and rapamycinin the treatment of multiple myeloma 33
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma 32
Totale 11.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.034
article - articoli 0
book - libri 0
conference - conferenze 5.115
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019692 0 0 0 39 51 51 53 143 36 60 179 80
2019/20201.152 58 51 45 146 74 186 153 94 109 88 88 60
2020/20211.902 121 58 158 145 173 122 146 129 192 193 207 258
2021/20222.691 152 163 194 244 200 195 282 229 156 210 333 333
2022/20232.914 236 206 101 248 260 540 265 205 289 198 180 186
2023/2024653 216 265 168 4 0 0 0 0 0 0 0 0
Totale 11.796